Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vigil Neuroscience, Inc. - Common Stock
(NQ:
VIGL
)
3.910
+0.190 (+5.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vigil Neuroscience, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
November 17, 2023
Via
Benzinga
US Stocks Edge Lower; Housing Starts Rise In October
November 17, 2023
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the market opening Friday, the Dow traded down 0.04% to 34,931.47 while the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Vigil Neuroscience
April 03, 2023
Via
Benzinga
Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation
October 18, 2023
JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
October 06, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 06, 2023
Via
Benzinga
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
September 26, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
September 21, 2023
Via
Benzinga
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
September 11, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
August 09, 2023
On Wednesday, 155 companies set new 52-week lows.
Via
Benzinga
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
September 07, 2023
On Thursday, 283 companies set new 52-week lows.
Via
Benzinga
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
August 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
July 13, 2023
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.
Via
MarketBeat
Topics
Retirement
Exposures
Pension
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
June 01, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 09, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
May 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
March 31, 2023
Via
Benzinga
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
March 30, 2023
Company remains on track to report interim data from Phase 2 trial in the second half of 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 27, 2023
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.